AOD9604

AOD9604 is a synthetic peptide fragment consisting of amino acids 177-191 from the C-terminal end of human growth hormone (hGH). Unlike full-length hGH, AOD9604 is designed to specifically target and regulate fat metabolism without stimulating growth or directly affecting insulin sensitivity. Its proposed mechanisms of action include:

• Stimulation of Lipolysis: Research suggests that AOD9604 may enhance the breakdown of stored fat (triglycerides) in adipose tissue. It is hypothesized to selectively stimulate the activity of hormone-sensitive lipase (HSL) and/or activate pathways that lead to fat mobilization.
• Inhibition of Lipogenesis: Studies indicate that AOD9604 may also inhibit lipogenesis, the process of synthesizing new fat molecules. This dual action aims to reduce both the accumulation and storage of fat.
• Interaction with Beta-3 Adrenergic Receptors (Proposed): Some research suggests that AOD9604's effects on fat metabolism might be partially mediated through its interaction with beta-3 adrenergic receptors, which are involved in thermogenesis and lipolysis in adipose tissue. However, this is an area of ongoing investigation.
• No Direct GH Receptor Binding: Crucially, AOD9604 lacks the hGH growth-promoting domain and does not appear to bind to the primary hGH receptor, thus avoiding the associated mitogenic (growth-promoting) and diabetogenic (insulin-resistance inducing) effects of full-length hGH.

These specific effects on fat metabolism position AOD9604 as a compound of interest for researchers studying obesity, metabolic syndrome, and related conditions, focusing on its potential as a targeted fat-reducing agent.

AOD9604 has a notable history in **clinical development** and continues to be a subject of **research focus**, primarily for its potential role in obesity and metabolic disorders. Its unique mechanism, separating fat metabolism from growth promotion, has led to various investigations.

• Obesity and Weight Management: Early clinical trials explored AOD9604 as a potential treatment for obesity, focusing on its ability to reduce body fat without affecting lean muscle mass or glucose homeostasis. These trials evaluated its impact on fat loss and overall body composition.
• Metabolic Syndrome: Research has investigated its broader effects on metabolic parameters beyond just fat reduction, such as lipid profiles and glucose regulation, in models of metabolic syndrome.
• Cartilage Repair and Osteoarthritis (Emerging Area): More recent preclinical research has explored unexpected potential applications, including its role in cartilage repair and joint health, suggesting possible anti-inflammatory and regenerative properties in orthopedic contexts.
• Safety Profile and Tolerability: Clinical studies have assessed its safety and tolerability profile, including potential side effects, in human subjects, contributing to its characterization as a research compound.

While some clinical trials have been conducted for specific indications, AOD9604 is currently supplied as a research chemical. Further research is needed to fully understand its therapeutic potential and long-term effects across various applications.

AOD9604 is strictly intended for **laboratory research purposes only**. It must be handled by qualified research personnel in a controlled laboratory environment, adhering to all applicable safety protocols and guidelines for investigational research chemicals. This product is **not approved for human consumption, therapeutic use, or veterinary applications**. Its use is limited to scientific investigation and analysis. Proper laboratory safety equipment, including personal protective equipment (PPE), and procedures must be employed during its handling, storage, and experimental application. Researchers should consult relevant safety data sheets (SDS) and institutional guidelines before use.

For more detailed information on AOD9604 and its research applications, please refer to the following scientific literature:

• Heffernan M, et al. "Effects of a synthetic a-hGH fragment on lipid metabolism in obese rats." J Endocrinol. 2001; PMID: 11713213 (Early study on lipid metabolism effects)
• Ng FM, et al. "Anti-obesity effects of a novel peptide, AOD9604, in obese rats." Int J Obes Relat Metab Disord. 2001; PMID: 11728216 (Another early study on anti-obesity effects)
• Christiansen JS, et al. "A 26-week study of the safety and efficacy of AOD9604 in obese adults." Int J Obes Relat Metab Disord. 2003; PMID: 14631379 (Clinical study on safety and efficacy in obese adults)
• Cosmetic peptides: an updated review: J Cosmet Dermatol, PMID: 24707168 (General review of cosmetic peptides, sometimes discusses related fragments)
• PubChem Compound Summary: AOD9604 (CID 156599045)

*(Note: These references provide a general overview of AOD9604 research.)*

This product, AOD9604, is sold exclusively for **research and development purposes**. It is classified as a research chemical and is **not a drug, food, or cosmetic**. It has not been evaluated or approved by the FDA or any other regulatory authority for safety, efficacy, or any other use in humans or animals. By purchasing this product, the user acknowledges and agrees to comply with all applicable local, national, and international laws and regulations regarding the handling, storage, and use of research compounds. Any use of this product for purposes other than legitimate scientific research is strictly prohibited and may lead to severe legal and health consequences.